Abstrato

PSMA PET/CT imaging and therapy

levent kabasakal and Emre Demirci

Prostate-specific membrane antigen (PSMA) is increasingly recognized as a novel target for the PET imaging of prostate cancer (PCa) and 68Ga-DKFZ-11 (68Ga-PSMA) has been suggested as a novel tracer for detection of PCa relapses and metastasis. First human studies of PSMA PET/CT imaging have demonstrated high tracer uptake at the sites of primary tumor and lymph node and bone metastasis in direct correlation with aggressiveness and Gleason scores. PSMA PET/ CT seems to be a highly accurate imaging tool for restaging of prostate cancer patients with biochemical recurrence. PSMA PET/CT imaging may be used in order to develop a treatment strategy for recurrent disease even in patients with low PSA levels. As a theranostic approach its counterpart Lu-177 labelled ligands have a potential role for the treatment of castration resistant prostate cancer.